Main findings and strengths
In the current study, we have developed and validated a score to predict deterioration based on a robust predictive model, which includes vital signs, but also other predictors related to age, comorbidities, number of medications, and lab test results. This score has shown excellent prognostic performance.
The strength of this research is the wide range of data used, and this has allowed us to obtain reliable results in a broad range of patients. Furthermore, the predictors used in the CDEWS are easily obtained from EHRs, allowing for real-time results. The diversity of the information used (demographic, clinical, etc.) suggests its applicability to all demographic groups.
The timeline we considered in this study is notably different from those focused on in previously proposed tools. Most of these other proposals, including the well-known MEWS9, aim to predict deterioration within 24 hours, seeking to prompt immediate intensification of care and avoid further deterioration. We retrieved earlier data, from 72 to 24 hours before the event, to set the threshold for triggering an alarm without altering usual care, allowing healthcare providers’ actions to be modified with enough time to obtain more information regarding vital signs or laboratory test results, i.e., implementing early monitoring. Given this, we suggest that CDEWS could be used together with other scores, that would be applied once the warming system’s alarm has been triggered.
Further, the variables found to be relevant in our study differ from those already used in other scales. In contrast to NEWS/MEWS9,10, temperature and heart rate were not significant in our model. This could be explained by our patients being relatively old, and older age being associated with physiological changes, such as baseline heart rate variability11 and a weaker response to infection12, suggesting that CDEWS could be an appropriate score regardless of the age group. Considering that scores’ performance might be influenced by age, Shamout et al. looked for an age-specific model1, and found that, rather than adding age to prognosis models, different scales performed better depending on the age range. We did not find differences in the risk of clinical deterioration in the age ranges between 45 and 85 years, perhaps due to lower statistical power in some age ranges, which could be a limitation of this work as well as the lack of data on frailty. We believe that further studies should include an age-frailty interaction term as a predictor and explore stratification of models according to age groups.
Among vital signs, only mean arterial pressure and oxygen saturation were retained in the model. As with the NEWS score, it could be argued that the use of oxygen saturation in the model makes it inappropriate for patients with chronic obstructive pulmonary disease 13. In our study, we opted to group comorbidities by systems, to make it simple to use. In that regard, 22% of the population was previously diagnosed with a chronic respiratory disease. Moreover, as many as 30% of the entire population were on medications related to the respiratory system, which makes us think that chronic respiratory disease could be underdiagnosed. Neither of those items had a significant influence in the prediction model, however, suggesting that the final model did work well for patients with chronic respiratory conditions. In any case, these questions need to be addressed in future prospective research.
Notably, in spite of considering all comorbidities for which data were available in our modeling, only neoplasms diagnosed in the year before admission was significant in the final prediction model, regardless of the stage of the disease. Cancer is one of the main causes of in-hospital death in Spain and also acts as a predictor of death or fatal conditions such as heart failure14,15.
Polypharmacy is strongly associated with frailty and several commonly prescribed drugs are strongly associated with increased mortality8. These factors explain its inclusion in the score, although none of the medication classes had a significant impact by themselves.
Redfern et al. used blood test results to enhance the predictive power of the NEWS 6. We chose to include not only the parameters already studied, such as potassium level, but also those related to acute disease and identified a positive impact of glucose and CRP.
Limitations and future research
As expected in retrospective research, some information was missing. Specifically, there were missing data on some clinical parameters, such as respiratory rate and mental status, due to incomplete recording under routine clinical practice conditions on hospital wards. To avoid this issue influencing the other results as well as to develop a tool suitable for use in routine clinical practice, we did not include these parameters in the model. Further, a substantial proportion of patients did not have laboratory samples collected daily; we opted to interpret the clinical decision as a sign of stability, and “no laboratory tests” was considered a value in itself. This assumption could have introduced bias, although it strengthened the statistical analysis.
The external validation of the model was performed in a different set of patients from the same hospital. On the other hand, the samples were obtained 2 years apart (during which time there may have been changes in clinical practice routines) and separated by the pandemic period, with the impact that this had both on patients’ chronic disease status16 and healthcare professional turnover. These factors suggest that the scenarios from which the datasets were obtained differed and in turn that it may be feasible to extrapolate our findings to other settings.
In a recent review, Henry et al pointed out the need for clinical deterioration scores validated in prospective studies, as well as the risk of increasing workload due to future use of prediction tools 17. These issues remain to be addressed for the score we propose, the CDEWS, underlining the need for new prospective studies in both the original hospital and other healthcare centers. From our point of view, the CDEWS should be integrated into care pathways as part of a multidisciplinary approach, to favor the success of the “ICU without walls” concept18. Furthermore, it could be tested as a tool to predict ICU readmission, as -to our knowledge- there are no effective tools for this purpose to date19.
Finally, although it can be envisaged that the simplicity of the CDEWS would make it easy to install it on any EHR device, further research is warranted to explore the fastest and most practical way to apply this tool in clinical settings. It is generally recognized that clinicians often use their own devices to obtain valuable data regarding the prognosis of their patients20. We believe that this kind of information should be automatically available for healthcare workers through the electronic devices used in routine clinical practice, and hence, one of the issues to be addressed is how best to implement this type of warning system for use in real-world settings.